secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fulgent Genetics, Inc. (FLGT)
CIK:        0001674930
Form:       8-K
Filed at:   2024-02-28T23:59:59+00:00
Accession:  0000950170-24-021645
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fulgent Genetics reports Q4 GAAP loss $128.1M; core revenue grows 21% YoY
-------------------------------------------------------------------------

- Full year total revenue $289.2M; core revenue (ex-COVID) grew 44% to $262.1M.
- Q4 total revenue $70.5M; core revenue grew 21% to $66.5M.
- Q4 GAAP net loss $128.1M ($4.30 per share); non-GAAP income $8.3M ($0.28 per share).
- Full year GAAP net loss $167.8M ($5.63 per share); non-GAAP loss $12.3M ($0.41 per share).
- Cash and investments $847.7M as of Dec 31, 2023; repurchased 953k shares for $25.1M in FY 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1674930/000095017024021645/0000950170-24-021645-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1674930/000095017024021645/flgt-20240228.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-021645

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer